This site is intended for US healthcare professionals only.
Address:
480 Pleasant Street
Suite B300
Watertown, MA 02472
1-833-EyePoint (1-833-393-7646)
This site is intended for US healthcare professionals only.
Listen to one patient tell her story about chronic noninfectious posterior uveitis and her treatment with YUTIQ. This is one patient’s experience. Your experience may differ.
Hypersensitivity: YUTIQ is contraindicated in patients with known hypersensitivity to any components of this product.
Intravitreal Injection-related Effects: Intravitreal injections, including those with YUTIQ, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. Hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection.
Steroid-related Effects: Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.
Risk of Implant Migration: Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.
In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.
©2019, EyePoint Pharmaceuticals, Inc. All rights reserved.
480 Pleasant Street, Suite B300, Watertown, MA 02472
YUTIQ is a registered trademark and the YUTIQ logo and the EyePoint logo are trademarks and EyePoint Assist is a service mark of EyePoint Pharmaceuticals, Inc.